Therefore, since cell viability experiments in parental and HER2-manipulated breast cancer cells functionally confirmed the differential EV-cell engagement, we reasonably concluded that the characterization of cell-interaction spectrum is a priority to optimize heterologous EVs as clinically suitable tools for targeted delivery. This evidence concerns the gene ERBB2 and breast cancer.